KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) EBT Margin (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of EBT Margin data on record, last reported at 297.04% in Q3 2025.

  • For Q3 2025, EBT Margin fell 14347.0% year-over-year to 297.04%; the TTM value through Sep 2025 reached 181.76%, down 240.0%, while the annual FY2024 figure was 121.1%, 18403.0% up from the prior year.
  • EBT Margin reached 297.04% in Q3 2025 per NKTR's latest filing, up from 352.53% in the prior quarter.
  • Across five years, EBT Margin topped out at 24.0% in Q4 2024 and bottomed at 736.47% in Q2 2022.
  • Average EBT Margin over 5 years is 345.7%, with a median of 297.04% recorded in 2025.
  • Peak YoY movement for EBT Margin: crashed -29467bps in 2022, then skyrocketed 48686bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 587.02% in 2021, then soared by 51bps to 288.16% in 2022, then soared by 41bps to 171.03% in 2023, then surged by 114bps to 24.0% in 2024, then crashed by -1338bps to 297.04% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 297.04% in Q3 2025, 352.53% in Q2 2025, and 443.3% in Q1 2025.